Munder Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Munder Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$110M	Sell	1,518,771 -19,512	-1%	-$1.28M	0.82%	27
2014 Q2	$95.7M	Sell	1,538,283 -72,013	-4%	-$4.35M	0.68%	52
2014 Q1	$110M	Buy	1,610,296 +5,911	+0.4%	+$436K	0.79%	36
2013 Q4	$113M	Sell	1,604,385 -12,671	-0.8%	-$861K	0.82%	31
2013 Q3	$117M	Buy	1,617,056 +12,527	+0.8%	+$833K	0.93%	20
2013 Q2	$89.4M	Buy	+1,604,529	New	+$100M	0.76%	37

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Munder Capital Management's BMRN Position: Q3 2014 in Review

Munder Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 1.3% in Q3 2014, selling an estimated $1.28M and leaving 1,518,771 shares worth $110M. The position accounts for 0.82% of the portfolio, ranked #27.

Munder Capital Management first reported a position in BMRN in Q2 2013 and has held it in 6 quarters since. The position peaked at $117M in Q3 2013. 316 funds tracked by Wall St. Rank hold BMRN as of Q3 2014.

Munder Capital Management held 1,518,771 shares of BioMarin Pharmaceuticals worth $110M as of Q3 2014.
Munder Capital Management sold 19,512 BioMarin Pharmaceuticals shares in Q3 2014, an estimated $1.28M.
BioMarin Pharmaceuticals made up 0.82% of Munder Capital Management's portfolio in Q3 2014, its #27 holding.
Munder Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
Munder Capital Management's BioMarin Pharmaceuticals position peaked at $117M in Q3 2013.
316 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2014.

Based on Munder Capital Management's 13F filing for Q3 2014, filed 31 Oct 2014.